

AroCell TK 210 ELISA Measurements are Central in Improved Cell Loss Metric

AroCell announced today the presentation made at ESMO Asia of further discoveries from the PROMIX breast cancer study. Combining serum Thymidine Kinase 1 (sTK1) measurements with routine pathologic markers improved the predictive power of a cell loss metric for tumour response to neoadjuvant chemotherapy in breast cancer.

The findings presented today at ESMO in Singapore are a continuation of results derived from sTK1 analysis of the PROMIX breast cancer study. At this same meeting in 2017 Professor Tribukait showed that it was possible to quantitate cell death with sTK1 measurements. Further careful analyses have discovered cell loss metrics useful in assessing therapy response. The predictive power of the cell loss metric studied, improved when combined with existing, previously collected clinical data such as hormone receptor status and tumour origin as obtained by routine histopathology at the time of diagnosis of the tumour.

"Combining diagnostic information at hand and the results from the AroCell TK 210 ELISA test can help gauge response, giving an early indication of therapy effectiveness. This will allow improved personalization of therapies." says Michael Brobjer, CEO of AroCell. "Clinicians have a lot of data to consider, but often lacking certainty and wishing for additional information. TK1 variations in blood have high correlation to abnormal cell death. With AroCell's test we look forward to assist researchers and clinicians worldwide, contributing information regarding TK1 levels in blood to benefit clinical studies and patients."

"This impressive post analysis work also shows that older studies with frozen samples preserved in blood banks may benefit greatly from individual TK1 assessments to gain further insights." concludes Michael Brobjer.

Link to the Abstract: [esmo.org](https://www.esmo.org)

About ESMO Asia Congress 2019:

ESMO (European Society of Medicinal Oncology) Asia Congress is one of the most important global oncology conferences with about 3,700 participants from over 70 countries. This year, EMSO is held between 22 and 24 November 2019 in Singapore, and it is the fifth time the conference is held.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[AroCell TK 210 ELISA Measurements are Central in Improved Cell Loss Metric](#)